Financial Results for the Fiscal Year Ended March 31, 2016
May 10, 2016
Exchange where listed: TSE

Name of listed company: TERUMO CORPORATION(URL http://www.terumo.com/): 4543: Yutaro Shintaku, President and CEO: Atsuo Omagari, General Manager, Corporate Communication Dept.
: +81 / 3-6742-8550

Company code number
Representative:
Please address all communications to
Phone

1. Consolidated Financial Highlights for the Year Ended March 2016
(From April 1, 2015 to March 31, 2016)(1) Consolidated operating results(Notes: The amounts shown below ignore values of less than a million yen)

Net sales%(Millions of yen)%

(Millions of yen)%

(Millions of yen)%

525,026
489,506

7.3
4.7

81,70367,45621.1
3.3

73,09070,7303.3
10.9

50,67638,47031.7
12.8

March 2016: 14,358 million yen (‐83.9%)

March 2015: 88,986 million yen (25.0%)

Net income per share,
fully diluted

Net income per share(Yen)

Year ended March, 2016
Year ended March, 2015
(Notes) Equity in earnings of affiliates:

Profit attributable toowners of parent

Ordinary income(Millions of yen)

Year ended March, 2016
Year ended March, 2015
(Notes) Comprehensive income:Operating income

Net income per stockholders'equity(Yen)

135.14101.33
March 2016: 328 million yen

126.36
99.12
March 2015: ‐65 million yen

Ordinary income
per total assets

Operating income
per Net sales

%

%

%

9.3
7.2

7.7
7.8

15.6
13.8

(2) Consolidated financial position
Total assets

Equity ratio

Net assets per share(Millions of yen)

%

(Yen)

901,685
992,073

511,544573,523

56.7
57.8

1,408.53
1,513.73

As of March 31, 2016
As of March 31, 2015
(Notes) Shareholders' equity:

Net assets(Millions of yen)March 31, 2016: 511,252 million yen

March 31, 2015: 573,444 million yen(3) Consolidated statements of cash flows

Year ended March, 2016
Year ended March, 2015

Cash flows fromoperating activities

Cash flows frominvesting activities

Cash flows fromfinancing activities(Millions of yen)

(Millions of yen)

(Millions of yen)

(Millions of yen)

80,303
73,110(23,495)(40,421)(79,936)
44,121

146,927
176,662

Cash and cash equivalents,
end of period

2. Dividends
Cash dividends per share
1st quarter

Year ended March, 2015
Year ended March, 2016
Year ending March, 2017 (forecast)

Total dividends(annual)

Total

Ratio of dividends
to net assets(consolidated)

Payout ratio(consolidated)

2nd quarter3rd quarter

4th quarter

(Yen)

(Yen)

(Yen)

(Yen)

(Yen)

(Millions of yen)

－
－
－

14.50
19.00
20.00

－
－
－

16.00
20.00
21.00

30.50
39.00
41.00

11,567
14,398

%

%

30.1
28.9
28.3

2.2
2.7

3. Consolidated Forecast for the Year Ending March 2017 (From April 1, 2016 to March 31, 2017)
Net sales(Millions of yen)

Operating income%(Millions of yen)%

(Millions of yen)

250,000
35,500(3.5)(9.2)
517,000
75,000Year ending March, 2017
(1.5)
(8.2)
(Notes) Assumed exchange rate for fiscal year ending March, 2016: USD1=JPY110, EUR1=JPY125

Half year ending September, 2016

Profit attributable toowners of parent

Ordinary income
32,50071,000Net income per share%(Millions of yen)

%

(Yen)

(9.1)
(2.9)

21,50052,500(20.4)
3.6

59.23
144.64

3.
Among the information that Terumo discloses, forecasts of financial performance on future projections contain potential risks and uncertainty since these are forecasts on
projections made by Terumo based on limited information available at the moment of disclosure. Accordingly, it should be noted that actual results may differ from those
forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo,
fluctuations of foreign exchange rates, and state of competition.

14. Financial Statements(1) Consolidated balance sheets(Millions of yen)
As of March 31, 2015

As of March 31, 2016

AmountAmount(Assets)I%
412,458

Cash and deposits

129,679

149,672

Noteｓ and accounts receivable-trade104,944

104,426

Marketable securities

50,000－Marchandise and finished goods

65,295

59,132Work in process

10,228

10,194

Raw materials and supplies

25,94827,126

Deferred tax assets

13,94914,963

Other

13,871

10,621

Allowance for doubtful accounts
II(1,458)

Noncurrent assets
1 Property, plant and equipment

374,746(1,390)58.0

521,657

57.9

178,49618.0

175,79419.5

60,78365,207

Machinery, equipment and vehicles

45,61654,362

Land

22,02323,297895

881

Construction in progress

39,02921,417

Other

10,1472 Intangible assets

331,990

10,62833.4

290,514Goodwill

166,990

143,707

Customer relationships

103,21790,750Other

61,78156,056

3 Investments and other assets

65,355Investment securities, including investments inunconsolidated subsidiaries and affiliates
Deferred tax assets

41.5

575,842

Buildings and structures

Lease assets

III

41.6

%

Current assets

6.6

55,34845,46137,724

259

3,436

32.3

6.1

Retirement benefit assets

6,786

－

Other

12,847

14,186

Deferred assets

3,772

0.4

5,281

0.6

992,073

100.0

901,685

100.0

Total assets2

(Millions of yen)
As of March 31, 2015

As of March 31, 2016

AmountAmount(Liabilities)
I%

Current liabilities

129,947

Notes and accounts payable-trade

38,48436,294

364

61

5,417

19,839

Short-term debt
Current portion of long-term debt
Lease obligations

168,835

208

256

－

40,000

Income taxes payable

19,714

9,778

Deferred tax liabilities

105

56

Provision for bonuses

5,560

5,869

Current portion of bonds payable

Provision for directors' bonuses
Notes and accounts payable-facilities

II

13.1

%

142

170

8,667

5,451

Other

51,282

Noncurrent liabilities

288,60251,05729.1

221,304

Bonds payable

40,000－Convertible bonds with subscription rights to shares

100,233

100,184

Long-term debt

79,141

58,873

Lease obligations
Deferred tax liabilities
Provision for directors' retirement benefits

18.7

278

286

50,01345,07966

66

Retirement benefit liabilities

7,020

8,656

Asset retirement obligations

233

230

24.6

Other

11,615

Total liabilities

418,55042.2

390,140

43.3

IShareholders' equity

471,10247.5

445,178

49.4

Capital stock

38,716

38,716

Capital surplus

52,10350,928Retained earnings

383,317419,573

Treasury stock
II

7,925

(3,035)

Accumulated other comprehensive income

102,341

Unrealized gains (losses) on available-for-sale securities,
net of taxes

16,910

Deferred gains (losses) on hedges, net of taxes(64,040)
10.3

66,074

7.3

16,308－(13)

Foreign currency translation adjustments, net of taxes

89,04363,182

Accumulated adjustments for retirement benefits, net of taxes(3,611)(13,403)

III

Stock subscription rights

78

0.0

183

0.0

IV

Non-controlling interests

－

－

109

0.0

Total net assets

573,52357.8

511,544

56.7

Total liabilities and net assets

992,073

100.0

901,685100.03

(2) Consolidated statements of income(Millions of yen)
For the year ended

For the year ended

March 31, 2015

March 31, 2016

AmountAmount%%I

Net sales

489,506

100.0

525,026

100.0

II

Cost of sales

233,48047.7

240,12545.7

256,02552.3

284,900

54.3

III

Selling, general and administrative expenses

188,56938.5

203,19738.7

67,45613.8

81,703

15.6

8,829

1.8

2,856

0.5

11,4682.2

Gross profit

Operating incomeIV

Non-operating income
Interest income

566

665

Dividends income

365

277

Royalty income

200

209

6,598

－

Foreign exchange gains
Equity in earnings of affiliates
Other
V

5,555

1.1

Interest expenses

1,254

1,395

Sales discounts

417

437

Foreign exchange losses

－

7,485

Equity in losses of affiliates

65－

Loss on disposal of inventories

267

82

Structural reform-related expenses

797

222

2,752

1,845

Ordinary income

70,73014.5

73,09013.9

Extraordinary income

3,282

0.7

7,494

1.5

3,665

0.7

Gain on sales of property, plant and equipment

692

Gain on sales of investment securities

559

793

－

1,783

Subsidy income
Gain on adjustment of accounts payable
VII

328
1,375

Non-operating expenses

Other

VI

－
1,098

4,917

2,030

Extraordinary expenses

－
9,965

2.1

Loss on disposal of property, plant and equipment

1,160

895

Impairment loss

1,625

1,010

Settlement paid

－

1,656

597

102

Loss on liquidation of subsidiaries
Restructuring loss
Loss on liquidation of businesses

5,607

－

974

－

Income before income taxes
VIII Income taxes
Current

29,954

Differed(4,378)

Profit64,046

13.1

76,92014.7

25,575

5.2

26,2905.0

50,6309.7

27,718(1,427)38,470Loss attributable to non-controlling interests
Profit attributable to owners of parent

4

7.9

－

－

(46)

(0.0)

38,4707.9

50,676

9.7

(3) Consolidated statements of comprehensive income(Millions of yen)
For the year ended
March 31, 2016
Amount

For the year ended
March 31, 2015
AmountI
II

ProfitOther comprehensive income
Valuation difference on available-for-sale securities
Deferred gains or losses on hedges
Foreign currency translation adjustments
Adjustments for retirement benefit
Share of other comprehensive income of associates
accounted for using equity method
Comprehensive income
Attributable to:38,47050,5155,640
245,665
(795)

(602)
(15)
(25,864)(9,792)1

Comprehensive income attributable to owners of parent
Comprehensive income attributable to non-controllinginterests

5

50,630(36,272)2
88,986

14,35888,986

14,408－(50)

(4) Statement of changes in net assets(Millions of yen)
Shareholders' equity
Year ended March 2015
Beginning of period
Cumulative effect of changes in accounting policies
Beginning of period as restated
Changes during this fiscal year
Dividends from surplus
Profit attributable to owners of parent
Purchase of treasury stock
Changes of items other than shareholders' equity (net)Total changes during this fiscal year
Ending of period

Capital stock

Capital surplus

Retained earnings

38,71652,10338,71652,103353,600
2,258
355,859(24)

Shareholders'equity total
444,396
2,258
446,655(3,010)(11,012)38,470(3,010)(3,010)(3,035)24,447471,102

Treasury stock(24)(11,012)38,470－38,716－52,10327,458383,317

Accumulated other comprehensive income

Year ended March 2015
Beginning of period
Cumulative effect of changes in accounting policies
Beginning of period as restated
Changes during this fiscal year
Dividends from surplus
Profit attributable to owners of parent
Purchase of treasury stock
Changes of items other than shareholders' equity (net)Total changes during this fiscal year
Ending of period

Valuation difference
on available-for-sale securities
11,269Remeasurements ofdefined benefit plans(2,816)

Accumulated othercomprehensive income total
51,828Subscription
rights toshares20

noncontrollinginterests(2)

Foreign currencytranslation adjustments
43,377(2)

43,377(2,816)

51,82820－

496,2452,258
498,504(11,012)38,470(3,010)50,57175,019573,523

Deferred gains orlosses on hedges

11,2695,640
5,640
16,9102
2－45,66545,66589,043－

Net assets
total

(795)
(795)
(3,611)50,51350,513102,341

58
58
78

－
－
－

Remeasurements ofdefined benefit plans(3,611)

Accumulated othercomprehensive income total
102,341

Subscription
rights toshares78

noncontrollinginterests－

Foreign currencytranslation adjustments
89,043－89,043(3,611)

102,34178－

573,523(2,396)571,126

109
109
109

(13,200)
50,676(61,004)(36,053)(59,582)
511,544(Millions of yen)
Shareholders' equity
Year ended March 2016
Beginning of period
Cumulative effect of changes in accounting policies
Beginning of period as restated
Changes during this fiscal year
Dividends from surplus
Profit attributable to owners of parent
Purchase of treasury stock
Changes of items other than shareholders' equity (net)Total changes during this fiscal year
Ending of period

Capital stock

Capital surplus

38,71652,103(1,175)50,92838,716

Retained earnings(3,035)

Shareholders'equity total
471,102(2,396)
468,706(61,004)(13,200)
50,676(61,004)(61,004)(64,040)(23,528)
445,178

Treasury stock

383,317(1,220)382,097(3,035)(13,200)
50,676－
38,716－50,92837,476
419,573

Accumulated other comprehensive income
Year ended March 2016
Beginning of period
Cumulative effect of changes in accounting policies
Beginning of period as restated
Changes during this fiscal year
Dividends from surplus
Profit attributable to owners of parent
Purchase of treasury stock
Changes of items other than shareholders' equity (net)Total changes during this fiscal year
Ending of period

Valuation difference
on available-for-sale securities
16,91016,910(602)(602)
16,308Deferred gains orlosses on hedges

(13)
(13)
(13)

(25,860)(25,860)
63,182

6(9,792)(9,792)(13,403)(36,267)(36,267)
66,074

105
105
183

－

Net assets
total

(5) Consolidated statements of cash flows

I(Millions of yen)

For the year ended

For the year ended

March 31, 2015

March 31, 2016

AmountAmountNet cash provided by (used in) operating activities
Income before income taxes

64,04676,920Depreciation and amortization

30,36333,679Impairment loss

1,625

1,010

Amortization of goodwill

10,32910,995Equity in losses (earnings) of affiliates

65

(328)

Decrease (increase) in retirement benefit assets

1,135(6,890)

Increase (decrease) in retirement benefit liabilities

(215)

(220)

Increase (decrease) in allowance for doubtful accounts

14

(22)

Increase (decrease) in provision for directors’ bonuses

32

28

(932)

(942)

Interest expense

1,254

1,395

Foreign exchange losses (gains)(4,483)4,321

Interest and dividend income

Structural reform-related expenses

797

222

Loss (gain) on sales of property, plant and equipment(692)(4,917)

Loss (gain) on disposal of property, plant and equipment

1,160

895

Loss (gain) on sales of investment securities

(559)

(793)

－

(1,783)

Subsidy income
Gain on adjustment of accounts payable
Settlement
Loss on liquidation of subsidiaries
Restructuring loss
Loss on liquidation of businesses(2,030)

－

－

1,656

597

102

5,607

－

974

－

Decrease (increase) in notes and accounts receivable-trade

1,317(3,138)Decrease (increase) in inventories(1,241)

398

(801)

(1,492)

Increase (decrease) in notes and accounts payable-trade
Other, net
Subtotal(2,242)

5,583

106,121116,679

Interest and dividends income received

1,165

1,751

Interest expenses paid

(1,282)(1,445)

Income taxes paid

(31,001)(36,451)

Payments for structural reform-related expenses
Subsidy income received

(382)

(409)

－

1,783

Payments for loss on liquidation of subsidiaries

(565)

(83)

Payments for restructuring loss

(515)

(1,390)

Payments for loss on liquidation of business

(179)

(132)

Payments for information system failure

(250)

－

73,11080,303(1,766)

Net cash provided by (used in) operating activities
II Net cash provided by (used in) investing activities
Payments into time deposits(1,201)

Proceeds from withdrawal of time deposits

1,505

1,796

Purchase of property, plant and equipment(37,342)(28,209)

Proceeds from sales of property, plant and equipment

1,168

5,135

Purchase of intangible assets(3,683)(4,703)Purchase of investment securities(429)(3,505)

Proceeds from sales of investment securities

1,434

10,802

Collection of lease deposits

459

39

Payments for acquisition of business

(54)

－

(2,276)(3,082)(40,421)(23,495)

Other, net
Net cash provided by (used in) investing activities
III Net cash provided by (used in) finacing activities
Proceeds from short-term debt

257－

Repayments of short-term debt

(202)

(298)

Proceeds from long-term debt

3,018

－

Repaymentｓ of long-term debt

(4,963)(5,416)

Proceeds from issuance of bonds with subscription rights to shares

100,250－

Redemption of bonds(40,000)

－

－

181

Proceeds from share issuance to non-controlling shareholders
Repayments of financial lease obligations

(214)

(197)

Purchase of treasury stock(3,010)(61,004)

Cash dividends paid

(11,012)(13,200)

44,121(79,936)

Net cash provided by (used in) finacing activities
IV Effect of exchange rate changes on cash and cash equivalents

7,353(6,606)

V Net increase(decrease) in cash and cash equivalents

84,164(29,734)

VI Cash and cash equivalents at beginning of the year

92,498

176,662

VII Cash and cash equivalents at end of the year

176,662

146,9277

(6)Notes<Significant accounting policies in preparing the consolidated financial statements>
Changes in accounting policy(Application of Accounting Standards regarding Business Combinations)
As the "Revised Accounting Standard for Business Combinations" (ASBJ Statement No.21, September 13, 2013; hereinafter the"Business Combinations Accounting Standard"), "Revised Accounting Standard for Consolidated Financial Statements" (ASBJ
Statement No.22, September 13, 2013; hereinafter the "Consolidation Accounting Standard"), "Revised Accounting Standard forBusiness Divestitures" (ASBJ Statement No.7, September 13, 2013; hereinafter the "Business Divestitures Accounting Standard")and other standards have been applied from the three months ended June 30, 2015. Accordingly, the accounting method has beenchanged that the difference associated with changes in equity in subsidiaries remaining under the control of the Company isrecorded as capital surplus, and acquisition-related costs are recorded as expenses for the fiscal year in which the costs are incurred.
For business combinations implemented on or after the beginning of the three months ended June 30, 2015, the accounting method
has been changed to reflect the adjustments to the allocated amount of acquisition costs on the finalization of provisional accounting
treatment in the consolidated financial statements for the quarter containing the date of the business combinations.
In addition, the Company has changed the presentation of net income, etc. as well as the presentation of minority interests to noncontrolling interests. To reflect these changes in presentation, the quarterly consolidated financial statements for the nine months
ended December 31, 2014 and consolidated financial statements for the fiscal year ended March 31, 2015 have been reclassified.
With respect to application of the Accounting Standards regarding Business Combinations, the transitional treatment as prescribedin article 58-2 (3) of the Business Combinations Accounting Standard, article 44-5 (3) of the Consolidation Accounting Standard andarticle 57-4 (3) of the Business Divestitures Accounting Standard was applied. The cumulative impact of the retroactive applicationof the new accounting policies over all past periods at the beginning of the three months ended June 30, 2015 was reflected in capitalsurplus and retained earnings.
As a result of this change, as of the beginning of the year ended March 31, 2016, goodwill, capital surplus and retained earnings
decreased by 3,135 million yen, 1,175 million yen and 1,220 million yen, respectively. Additionally operating income, ordinary
income, and income before income taxes for the year ended March 31, 2016 all increased by 188 million yen.
Reflecting the cumulative impact on net assets at the beginning of the year ended March 31, 2016, in the consolidated statement ofchanges in net assets, capital surplus at the beginning decreased by 1,175 million yen and retained earnings at the beginning
decreased by 1,220 million yen.
In addition, net assets per share for the fiscal year ended March 31, 2016, decreased by 6.08 yen and net income per share and net
income per share, fully diluted increased by 0.50 yen and 0.47 yen, respectively.

8

5. Segment Information[Reportable Segments](1) Fiscal Year Ended March 31, 2015

(Millions of yen)
Reportable Segments
Cardiac and
VascularCompany

GeneralHospitalCompany

Blood
Management
Company

Adjustment

Total

Subtotal

Sales and operating income:Sales to customer
Internal sales
Sales total

226,944

161,462

101,099

489,506

－

－

－

－

－

－

489,506－

226,944

161,462

101,099

489,506－

489,506

Segment income (Excl. Amortization)

47,437

20,833

18,54086,811(1,676)

85,134

Segment income (loss)

45,672

20,833

2,626

69,132(1,676)67,456

20.9

12.9

18.3

17.7

－

241,401

196,842

382,438

820,683

171,389

992,073

Depreciation and amortization

7,450

8,584

12,93528,9701,392

30,363

Amortization of goodwill
Net increase of tangible andintangible noncurrent assets

1,764

－

8,564

10,329－10,32916,97812,24011,43440,653788

41,441

Segment income(%)(Excl. Amortization)
Segment assets

17.4

Others:

Notes: 1. The (1,676) million yen adjustment to segment income is the sum of (1,541) million yen for inventories and (134)
million yen for others.
2. Adjustment to segment assets, which amounted to 171,389 million yen, mainly includes investments in"Cash anddeposit", "Investments securities", "Deferred tax assets" and assets of the Administrative Department.

(2) Fiscal Year Ended March 31, 2016

(Millions of yen)
Reportable Segments
Cardiac and
VascularCompany

GeneralHospitalCompany

Blood
Management
Company

Adjustment

Total

Subtotal

Sales and operating income:Sales to customer

258,600

161,382

105,042525,026

－

－

－

－

－

－

－

Sales total

258,600

161,382

105,042525,026－

525,026

Segment income (Excl. Amortization)

63,41922,613

16,944

102,977(1,121)

101,855

Segment income (loss)

61,616

22,613(1,405)82,824(1,121)

81,703

24.5

14.0

16.1

19.6

－

241,798

166,727

326,728735,254

Depreciation and amortization

9,181

9,938

13,752

Amortization of goodwill
Net increase of tangible andintangible noncurrent assets

1,803

－

9,191

15,526

8,507

7,218

Internal sales

Segment income(%)(Excl. Amortization)
Segment assets

525,026

19.4

166,431901,685

32,872806

33,67910,995－

10,99531,252201

31,454

Others:

Notes: 1. The (1,121) million yen adjustment to segment income is the sum of (1,096) million yen for inventories and (24)
million yen for others.
2. Adjustment to segment assets, which amounted to 166,431million yen, mainly includes investments in"Cash anddeposit", "Investments securities", "Deferred tax assets" and assets of the Administrative Department.

9

(Changes in the category of segments)
As a result of reclassification in performance management among overseas subsidiaries, “Harvest Technologies Corporation”
and “Harvest Technologies GmbH” have been transferred from “Cardiac and Vascular Company” to “Blood Management
Company” since October 1, 2014. “Segment income” has been adjusted retrospectively to reflect the effect of this change.

(Note) Main products belonging to each business segment
Business segments
Sub-segments
Interventional Systems (TIS)

Cardiac and Vascular Company

General Hospital Company

Blood Management Company

Main products
Angiographic catheters, PTCA balloon catheters,
Coronary stents, etc.

Neurovascular

Neuro interventional coils, etc.

CV Systems

Oxygenators, Cardio-pulmonary bypass system,
etc.

Vascular Graft

Artificial vascular grafts, Stent grafts

General Hospital Products

Solution sets, I.V.catheters, Infusion pumps,
Syringe pumps, Syringes, Needles, Bloodcollection tubes, etc.

D&D

Prefilled syringes, Pain management systems,
I.V.solutions, Nutritious food, CAPD systems,
etc.

DM and Consumer Healthcare

Blood glucose monitoring systems, Digital
thermometers, Blood pressure monitors, etc.

－10Blood bags, Automated blood collection system,
Automated blood component processing system,
Centrifugal apheresis system, Cell expansion
system, etc.

(Supplementary Information)[Geographic Segments](1) Fiscal year ended March 31, 2015

(Millions of yen)Japan

Americas

EuropeAsia and others

Total(United states)

Sales

183,146

104,600

125,310

104,396

76,448489,506

Tangible noncurrent assets

110,226

10,18025,687

15,86232,402

178,496(2) Fiscal year ended March 31, 2016

(Millions of yen)Japan

Americas

Europe(United states)

Asia and others

Total

Sales

187,210

101,802

143,462

122,559

92,550525,026

Tangible noncurrent assets

106,223

9,754

29,446

19,71430,369

175,794[Impairment Loss on noncurrent assets](1) Fiscal year ended March 31, 2015

(Millions of yen)
Reportable Segments
Cardiac and
VascularCompany

Impairment Loss

1,625

General HospitalCompany

Blood
Management
Company－－

SubtotalCompany

1,625(2) Fiscal year ended March 31, 2016

Total
－

1,625

(Millions of yen)
Reportable Segments
Cardiac and
VascularCompany

Impairment Loss

876

General HospitalCompany

Blood
Management
Company－

SubtotalCompany
876

－

Total

134

1,010

[Goodwill](1) Fiscal year ended March 31, 2015

(Millions of yen)
Reportable Segments
Cardiac and
VascularCompany

Goodwill

17,648General HospitalCompany

Blood
Management
Company－

149,342

SubtotalCompany

166,990(2) Fiscal year ended March 31, 2016

Total
－

166,990(Millions of yen)
Reportable Segments
Cardiac and
VascularCompany

Goodwill

14,997

General HospitalCompany

Blood
Management
Company－

128,710

11

Subtotal
143,707

Company

Total－

143,707

6. Significant subsequent events<Issuance of bonds>
Terumo corporation issued unsecured straight bonds with a payment date of April 19, 2016 upon a resolution of the Board of
Directors held on April 5, 2016. The terms and conditions are as follows.
Terumo Corporation Series 5 Unsecured Straight Bonds (with inter-bond parri passu clause) (5-year Bond)
1. Total amount of issue: 10 billion yen: 100% of the principal amount
2. Issuance price: 0.080% per annum
3. Interest rate
4. Payment date
: April 19, 2016
5. Maturity: April 19, 2021
6. Redemption: Lump-sum redemption at maturity: The funds will be appropriated to the repayment of the loan which will become due in February, 2017
7. Use of funds
and a part of the redemption of corporate bonds.
Terumo Corporation Series 6 Unsecured Straight Bonds (with inter-bond parri passu clause) (7-year Bond)
1. Total amount of issue: 10 billion yen: 100% of the principal amount
2. Issuance price: 0.170% per annum
3. Interest rate
4. Payment date
: April 19, 2016
5. Maturity: April 19, 2023
6. Redemption: Lump-sum redemption at maturity: The funds will be appropriated to the repayment of the loan which will become due in February, 2017
7. Use of funds
and a part of the redemption of corporate bonds.
Terumo Corporation Series 7 Unsecured Straight Bonds (with inter-bond parri passu clause) (10-year Bond)
1. Total amount of issue: 10 billion yen: 100% of the principal amount
2. Issuance price: 0.240% per annum
3. Interest rate
4. Payment date
: April 19, 2016
5. Maturity: April 17, 2026
6. Redemption: Lump-sum redemption at maturity: The funds will be appropriated to the repayment of the loan which will become due in February, 2017
7. Use of funds
and a part of the redemption of corporate bonds.

12